



## RIFM fragrance ingredient safety assessment, *d*-8-*p*-menthene-1,2-epoxide, CAS Registry Number 1195-92-2

A.M. Api<sup>a</sup>, D. Belsito<sup>b</sup>, D. Botelho<sup>a</sup>, M. Bruze<sup>c</sup>, G.A. Burton Jr.<sup>d</sup>, M.A. Cancellieri<sup>a</sup>, H. Chon<sup>a</sup>, M.L. Dagli<sup>e</sup>, M. Date<sup>a</sup>, W. Dekant<sup>f</sup>, C. Deodhar<sup>a</sup>, A.D. Fryer<sup>g</sup>, L. Jones<sup>a</sup>, K. Joshi<sup>a</sup>, M. Kumar<sup>a</sup>, A. Lapczynski<sup>a</sup>, M. Lavelle<sup>a</sup>, I. Lee<sup>a</sup>, D.C. Liebler<sup>h</sup>, H. Moustakas<sup>a</sup>, M. Na<sup>a</sup>, T.M. Penning<sup>i</sup>, G. Ritacco<sup>a</sup>, J. Romine<sup>a</sup>, N. Sadekar<sup>a</sup>, T.W. Schultz<sup>j</sup>, D. Selechnik<sup>a</sup>, F. Siddiqi<sup>a</sup>, I.G. Sipes<sup>k</sup>, G. Sullivan<sup>a,\*</sup>, Y. Thakkar<sup>a</sup>, Y. Tokura<sup>l</sup>

<sup>a</sup> Research Institute for Fragrance Materials, Inc., 50 Tice Boulevard, Woodcliff Lake, NJ, 07677, USA

<sup>b</sup> Member Expert Panel for Fragrance Safety, Columbia University Medical Center, Department of Dermatology, 161 Fort Washington Ave., New York, NY, 10032, USA

<sup>c</sup> Member Expert Panel for Fragrance Safety, Malmö University Hospital, Department of Occupational & Environmental Dermatology, Sodra Forstadsgatan 101, Entrance 47, Malmö, SE, 20502, Sweden

<sup>d</sup> Member Expert Panel for Fragrance Safety, School of Natural Resources & Environment, University of Michigan, Dana Building G110, 440 Church St., Ann Arbor, MI, 48109, USA

<sup>e</sup> Member Expert Panel for Fragrance Safety, University of Sao Paulo, School of Veterinary Medicine and Animal Science, Department of Pathology, Av. Prof. dr. Orlando Marques de Paiva, 87, Sao Paulo, CEP 05508-900, Brazil

<sup>f</sup> Member Expert Panel for Fragrance Safety, University of Würzburg, Department of Toxicology, Versbacher Str. 9, 97078, Würzburg, Germany

<sup>g</sup> Member Expert Panel for Fragrance Safety, Oregon Health & Science University, 3181 SW Sam Jackson Park Rd., Portland, OR, 97239, USA

<sup>h</sup> Member Expert Panel for Fragrance Safety, Vanderbilt University School of Medicine, Department of Biochemistry, Center in Molecular Toxicology, 638 Robinson Research Building, 2200 Pierce Avenue, Nashville, TN, 37232-0146, USA

<sup>i</sup> Member of Expert Panel for Fragrance Safety, University of Pennsylvania, Perelman School of Medicine, Center of Excellence in Environmental Toxicology, 1316 Biomedical Research Building (BRB) II/III, 421 Curie Boulevard, Philadelphia, PA, 19104-3083, USA

<sup>j</sup> Member Expert Panel for Fragrance Safety, The University of Tennessee, College of Veterinary Medicine, Department of Comparative Medicine, 2407 River Dr., Knoxville, TN, 37996-4500, USA

<sup>k</sup> Member Expert Panel for Fragrance Safety, Department of Pharmacology, University of Arizona, College of Medicine, 1501 North Campbell Avenue, P.O. Box 245050, Tucson, AZ, 85724-5050, USA


<sup>l</sup> Member Expert Panel for Fragrance Safety, The Journal of Dermatological Science (JDS), Editor-in-Chief, Professor and Chairman, Department of Dermatology, Hamamatsu University School of Medicine, 1-20-1 Handayama, Higashi-ku, Hamamatsu, 431-3192, Japan

### ARTICLE INFO

Handling Editor: Dr. Jose Luis Domingo

Version: 121521. Initial publication. All fragrance materials are evaluated on a five-year rotating basis. Revised safety assessments are published if new relevant data become available. Open access to all RIFM Fragrance Ingredient Safety Assessments is here: [fragrancematerialsafetysource.elsevier.com](http://fragrancematerialsafetysource.elsevier.com).

Name: *d*-8-*p*-Menthene-1,2-epoxide  
CAS Registry Number: 1195-92-2  
Additional CAS\*:



(continued on next column)

(continued)

203719-53-3 L-8-*p*-Menthene-1,2-epoxide  
(no reported use)  
\*Included because the materials are isomers

#### Abbreviation/Definition List:

**2-Box Model** - A RIFM, Inc. proprietary *in silico* tool used to calculate fragrance air exposure concentration  
**AF** - Assessment Factor  
**BCF** - Bioconcentration Factor

(continued on next page)

\* Corresponding author.

E-mail address: [gsullivan@rifm.org](mailto:gsullivan@rifm.org) (G. Sullivan).

<https://doi.org/10.1016/j.fct.2022.113259>

Received 15 December 2021; Accepted 21 June 2022

Available online 24 June 2022

0278-6915/© 2022 Elsevier Ltd. All rights reserved.

(continued)

**CNIH** – Confirmation of No Induction in Humans test. A human repeat insult patch test that is performed to confirm an already determined safe use level for fragrance ingredients (Na et al., 2021)

**Creme RIFM Model** - The Creme RIFM Model uses probabilistic (Monte Carlo) simulations to allow full distributions of data sets, providing a more realistic estimate of aggregate exposure to individuals across a population (Comiskey et al., 2015, 2017; Safford et al., 2015a, 2017) compared to a deterministic aggregate approach

**DEREK** - Derek Nexus is an *in silico* tool used to identify structural alerts

**DRF** - Dose Range Finding

**DST** - Dermal Sensitization Threshold

**ECHA** - European Chemicals Agency

**ECOSAR** - Ecological Structure-Activity Relationships Predictive Model

**EU** - Europe/European Union

**GLP** - Good Laboratory Practice

**IFRA** - The International Fragrance Association

**LOEL** - Lowest Observable Effect Level

**MOE** - Margin of Exposure

**MPPD** - Multiple-Path Particle Dosimetry. An *in silico* model for inhaled vapors used to simulate fragrance lung deposition

**NA** - North America

**NESIL** - No Expected Sensitization Induction Level

**NOAEC** - No Observed Adverse Effect Concentration

**NOAEL** - No Observed Adverse Effect Level

**NOEC** - No Observed Effect Concentration

**NOEL** - No Observed Effect Level

**OECD** - Organisation for Economic Co-operation and Development

**OECD TG** - Organisation for Economic Co-operation and Development Testing Guidelines

**PBT** - Persistent, Bioaccumulative, and Toxic

**PEC/PNEC** - Predicted Environmental Concentration/Predicted No Effect Concentration

**Perfumery** - In this safety assessment, perfumery refers to fragrances made by a perfumer used in consumer products only. The exposures reported in the safety assessment include consumer product use but do not include occupational exposures

**QRA** - Quantitative Risk Assessment

**QSAR** - Quantitative Structure-Activity Relationship

**REACH** - Registration, Evaluation, Authorisation, and Restriction of Chemicals

**RfD** - Reference Dose

**RIFM** - Research Institute for Fragrance Materials

**RQ** - Risk Quotient

**Statistically Significant** - Statistically significant difference in reported results as compared to controls with a  $p < 0.05$  using appropriate statistical test

**TTC** - Threshold of Toxicological Concern

**UV/Vis spectra** - Ultraviolet/Visible spectra

**VCF** - Volatile Compounds in Food

**VoU** - Volume of Use

**vPvB** - (very) Persistent, (very) Bioaccumulative

**WoE** - Weight of Evidence

**The Expert Panel for Fragrance Safety\* concludes that this material is safe as described in this safety assessment.**

This safety assessment is based on the RIFM Criteria Document (Api, 2015), which should be referred to for clarifications.

Each endpoint discussed in this safety assessment includes the relevant data that were available at the time of writing (version number in the top box is indicative of the date of approval based on a 2-digit month/day/year), both in the RIFM Database (consisting of publicly available and proprietary data) and through publicly available information sources (e.g., SciFinder and PubMed). Studies selected for this safety assessment were based on appropriate test criteria, such as acceptable guidelines, sample size, study duration, route of exposure, relevant animal species, most relevant testing endpoints, etc. A key study for each endpoint was selected based on the most conservative endpoint value (e.g., PNEC, NOAEL, LOEL, and NESIL).

\*The Expert Panel for Fragrance Safety is an independent body that selects its own members and establishes its own operating procedures. The Expert Panel is comprised of internationally known scientists that provide RIFM with guidance relevant to human health and environmental protection.

**Summary: The existing information supports the use of this material as described in this safety assessment.**

*d*-8-*p*-Menthene-1,2-epoxide was evaluated for genotoxicity, repeated dose toxicity, reproductive toxicity, local respiratory toxicity, phototoxicity/photoallergenicity, skin sensitization, and environmental safety. Data show that *d*-8-*p*-menthene-1,2-epoxide is not genotoxic. The repeated dose, reproductive, and local respiratory toxicity endpoints were evaluated using the Threshold of Toxicological Concern (TTC) for a Cramer Class III material, and the exposure to *d*-8-*p*-menthene-1,2-epoxide is below the TTC (0.0015 mg/kg/day, 0.0015 mg/kg/day, and 0.47 mg/

(continued on next column)

(continued)

day, respectively). The skin sensitization endpoint was completed using the Dermal Sensitization Threshold (DST) for reactive materials (64  $\mu\text{g}/\text{cm}^2$ ); exposure is below the DST. The phototoxicity/photoallergenicity endpoints were evaluated based on ultraviolet/visible (UV/Vis) spectra; *d*-8-*p*-menthene-1,2-epoxide is not expected to be phototoxic/photoallergenic. The environmental endpoints were evaluated; *d*-8-*p*-menthene-1,2-epoxide was found not to be Persistent, Bioaccumulative, and Toxic (PBT) as per the International Fragrance Association (IFRA) Environmental Standards, and its risk quotients, based on its current volume of use in Europe and North America (i.e., Predicted Environmental Concentration/Predicted No Effect Concentration [PEC/PNEC]), are  $< 1$ .

#### Human Health Safety Assessment

**Genotoxicity:** Not genotoxic. (RIFM, 2017b; RIFM, 2018; RIFM, 2017a; RIFM, 2021)

**Repeated Dose Toxicity:** No NOAEL available. Exposure is below the TTC.

**Reproductive Toxicity:** No NOAEL available. Exposure is below the TTC.

**Skin Sensitization:** Exposure is below the DST.

**Phototoxicity/Photoallergenicity:** Not expected to be phototoxic/photoallergenic. (UV/Vis Spectra; RIFM Database)

**Local Respiratory Toxicity:** No NOAEC available. Exposure is below the TTC.

#### Environmental Safety Assessment

##### Hazard Assessment:

**Persistence:** Screening-level: 2.64 (BIOWIN 3) (EPI Suite v4.11; US EPA, 2012a)

**Bioaccumulation:** Screening-level: 60.03 L/kg (EPI Suite v4.11; US EPA, 2012a)

**Ecotoxicity:** Screening-level: Fish LC50: 11.71 mg/L (RIFM Framework; Salvitto, 2002)

**Conclusion:** Not PBT or vPvB as per IFRA Environmental Standards

##### Risk Assessment:

**Screening-level:** PEC/PNEC (North America and Europe)  $< 1$  (RIFM Framework; Salvitto, 2002)

**Critical Ecotoxicity Endpoint:** Fish LC50: 11.71 mg/L (RIFM Framework; Salvitto, 2002)

**RIFM PNEC is:** 0.01171  $\mu\text{g}/\text{L}$

• **Revised PEC/PNECs (2015 IFRA VoU):** North America (No VoU) and Europe: Not applicable; cleared at screening-level

## 1. Identification

|   |   |
|---|---|
| <b>Chemical Name:</b> <i>d</i> -8- <i>p</i> -Menthene-1,2-epoxide   | <b>Chemical Name:</b> <i>L</i> -8- <i>p</i> -Menthene-1,2-epoxide   |
| <b>CAS Registry Number:</b> 1195-92-2   | <b>CAS Registry Number:</b> 203719-53-3   |
| <b>Synonyms:</b> D-1,2-Epoxy limonene; D-Limonene 1,2-epoxide; (4R)-1-Methyl-4-(prop-1-en-2-yl)-7-oxabicyclo[4.1.0]heptane; L-1,2-Epoxy limonene; L-Limonene 1,2-epoxide; L-8- <i>p</i> -Menthene-1,2-epoxide | <b>Synonyms:</b> (4S)-1-Methyl-4-(prop-1-en-2-yl)-7-oxabicyclo[4.1.0]heptane; L-1,2-Epoxy limonene; L-Limonene 1,2-epoxide; L-8- <i>p</i> -Menthene-1,2-epoxide |
| <b>Molecular Formula:</b> C <sub>10</sub> H <sub>16</sub> O   | <b>Molecular Formula:</b> C <sub>10</sub> H <sub>16</sub> O   |
| <b>Molecular Weight:</b> 152.23 g/mol   | <b>Molecular Weight:</b> 152.23 g/mol   |
| <b>RIFM Number:</b> 6700  | <b>RIFM Number:</b> No RIFM Number  |
| <b>Stereochemistry:</b> D (4R) isomer specified. Two stereocenters and 4 total stereoisomers possible.  | <b>Stereochemistry:</b> L (4S) isomer specified. Two stereocenters and 4 total stereoisomers possible.  |

## 2. Physical data

|  |  |
|--|--|
| <b>CAS #</b> 1195-92-2   | <b>CAS #</b> 203719-53-3                 |
| <b>Boiling Point:</b> 175.99 °C (EPI Suite)  | <b>Boiling Point:</b> Not Available      |
| <b>Flash Point:</b> Not Available  | <b>Flash Point:</b> Not Available        |
| <b>Log K<sub>OW</sub>:</b> 3.43 (EPI Suite)  | <b>Log K<sub>OW</sub>:</b> Not Available |
| <b>Melting Point:</b> -9.37 °C (EPI Suite)   | <b>Melting Point:</b> Not Available      |
| <b>Water Solubility:</b> 137.2 mg/L (EPI Suite)  | <b>Water Solubility:</b> Not Available   |
| <b>Specific Gravity:</b> Not Available   | <b>Specific Gravity:</b> Not Available   |
| <b>Vapor Pressure:</b> 1.13 mm Hg at 20 °C (EPI Suite v4.0), 1.59 mm Hg at 25 °C (EPI Suite) | <b>Vapor Pressure:</b> Not Available     |

(continued on next page)

(continued)

|   |   |
|---|---|
| <b>UV Spectra:</b> No absorbance between 290 and 700 nm; molar absorption coefficient is below the benchmark (1000 L mol <sup>-1</sup> • cm <sup>-1</sup> ) | <b>UV Spectra:</b> Not Available              |
| <b>Appearance/Organoleptic:</b> Not Available   | <b>Appearance/Organoleptic:</b> Not Available |

### 3. Volume of use (worldwide band)

1. <0.1 metric ton per year (IFRA, 2015)

### 4. Exposure to fragrance ingredient (Creme RIFM aggregate exposure model v1.0)\*

1. **95th Percentile Concentration in Fine Fragrance:** 0.00087% (RIFM, 2019)
2. **Inhalation Exposure\*\*:** 0.0000002 mg/kg/day or 0.000012 mg/day (RIFM, 2019)
3. **Total Systemic Exposure\*\*\*:** 0.0000050 mg/kg/day (RIFM, 2019)

\*When a safety assessment includes multiple materials, the highest exposure out of all included materials will be recorded here for the 95th Percentile Concentration in fine fragrance, inhalation exposure, and total exposure.

\*\*95th percentile calculated exposure derived from concentration survey data in the Creme RIFM Aggregate Exposure Model (Comiskey, 2015, 2017; Safford, 2015a, 2017).

\*\*\*95th percentile calculated exposure; assumes 100% absorption unless modified by dermal absorption data as reported in Section V. It is derived from concentration survey data in the Creme RIFM Aggregate Exposure Model and includes exposure via dermal, oral, and inhalation routes whenever the fragrance ingredient is used in products that include these routes of exposure (Comiskey, 2015, 2017; Safford, 2015a, 2017).

### 5. Derivation of systemic absorption

1. **Dermal:** Assumed 100%
2. **Oral:** Assumed 100%
3. **Inhalation:** Assumed 100%

### 6. Computational toxicology evaluation

#### 6.1. Cramer Classification

Class III, High.

| Expert Judgment | Toxtree v3.1 | OECD QSAR Toolbox v4.2 |
|-----------------|--------------|------------------------|
| III             | III          | III                    |

#### 6.2. Analogs selected

- a. **Genotoxicity:** None
- b. **Repeated Dose Toxicity:** None
- c. **Reproductive Toxicity:** None
- d. **Skin Sensitization:** None
- e. **Phototoxicity/Photoallergenicity:** None
- f. **Local Respiratory Toxicity:** None
- g. **Environmental Toxicity:** None

#### 6.3. Read-across justification

None.

### 7. Metabolism

No relevant data available for inclusion in this safety assessment.  
**Additional References:** None.

### 8. Natural occurrence

*d*-8-*p*-Menthene-1,2-epoxide is reported to occur in the following foods by the VCF\*:

|   |                                    |
|---|------------------------------------|
| Angelica ( <i>Angelica archangelica</i> L.)     | Ginger ( <i>Zingiber species</i> ) |
| Cardamom ( <i>Ellettaria cardamomum</i> Maton.) | Pepper ( <i>Piper nigrum</i> L.)   |
| Citrus Fruits                                   | <i>Pistacia atlantica</i>          |
| Dill ( <i>Anethum</i> species)                  | Tea                                |

\*VCF (Volatile Compounds in Food): Database/Nijssen, L.M.; Ingen-Visscher, C.A. van; Donders, J.J.H. (eds). – Version 15.1 – Zeist (The Netherlands): TNO Triskelion, 1963–2014. A continually updated database containing information on published volatile compounds that have been found in natural (processed) food products. Includes FEMA GRAS and EU-Flavis data.

### 9. REACH dossier

*d*-8-*p*-Menthene-1,2-epoxide has been pre-registered for 2010; L-8-*p*-Menthene-1,2-epoxide has not been pre-registered; no dossiers available as of 12/15/21.

### 10. Conclusion

The existing information supports the use of this material as described in this safety assessment.

### 11. Summary

#### 11.1. Human health endpoint summaries

##### 11.1.1. Genotoxicity

Based on the current existing data, *d*-8-*p*-menthene-1,2-epoxide does not present a concern for genotoxicity.

**11.1.1.1. Risk assessment.** The mutagenic activity of *d*-8-*p*-menthene-1,2-epoxide has been evaluated in a bacterial reverse mutation assay conducted in compliance with GLP regulations and in accordance with OECD TG 471 using the standard plate incorporation method. *Salmonella typhimurium* strains TA98, TA100, TA1535, TA1537, and *Escherichia coli* strain WP2uvrA were treated with *d*-8-*p*-menthene-1,2-epoxide in dimethyl sulfoxide (DMSO) at concentrations up to 5000 µg/plate. Increases in the mean number of revertant colonies were observed in WP2uvrA with and without S9 (RIFM, 2017b). Under the conditions of the study, *d*-8-*p*-menthene-1,2-epoxide was mutagenic in the Ames test.

A mammalian cell gene mutation assay (HPRT) was conducted according to OECD TG 476/GLP guidelines. Mouse lymphoma L5178Y cells were treated with *d*-8-*p*-menthene-1,2-epoxide in DMSO at concentrations up to 550 µg/mL (as determined in a preliminary toxicity assay) for 3 h. Effects were evaluated both with and without metabolic activation. No statistically significant increases in the frequency of mutant colonies were observed with any concentration of the test material, either with or without metabolic activation (RIFM, 2018). Under the conditions of the study, *d*-8-*p*-menthene-1,2-epoxide was not mutagenic to mammalian cells *in vitro*.

The clastogenic activity of *d*-8-*p*-menthene-1,2-epoxide was evaluated in an *in vitro* micronucleus test conducted in compliance with GLP regulations and in accordance with OECD TG 487. Human peripheral blood lymphocytes were treated with *d*-8-*p*-menthene-1,2-epoxide in DMSO at concentrations up to 1522 µg/mL in a dose range finding (DRF)

study; micronuclei analysis was conducted at concentrations up to 550 µg/mL in the presence and absence of metabolic activation. *d*-8-*p*-Menthene-1,2-epoxide did not induce binucleated cells with micronuclei when tested up to cytotoxic levels in either the presence or absence of an S9 activation system (RIFM, 2017a). Under the conditions of the study, *d*-8-*p*-menthene-1,2-epoxide was considered to be non-clastogenic in the *in vitro* micronucleus test.

A GLP-compliant 3D reconstructed skin micronucleus (RSMN) assay was conducted to evaluate the genotoxic potential of *d*-8-*p*-menthene-1,2-epoxide (CAS # 1195-92-2) in Phenion Full-Thickness Skin Model tissues. Acetone was used as the vehicle. Phenion Full-Thickness Skin Model tissues were treated with *d*-8-*p*-menthene-1,2-epoxide at 24-h intervals for 48 h, at concentrations up to 250 µg/cm<sup>2</sup>. *d*-8-*p*-Menthene-1,2-epoxide did not induce binucleated cells with micronuclei when tested up to cytotoxic-level concentrations and therefore was concluded to be negative for the induction of micronuclei in the RSMN in Phenion Full-Thickness Skin Model tissues (RIFM, 2021).

Negative results in mammalian cell tests that cover clastogenic, aneugenic, and gene mutation endpoints could indicate that a material producing adverse Ames data is not likely to be carcinogenic or genotoxic *in vivo* (Kirkland, 2014).

Based on the data available, *d*-8-*p*-menthene-1,2-epoxide does not present a concern for genotoxic potential.

**Additional References:** None.

**Literature Search and Risk Assessment Completed On:** 10/19/21.

#### 11.1.2. Repeated dose toxicity

There are insufficient repeated dose toxicity data on *d*-8-*p*-menthene-1,2-epoxide or any read-across materials. The total systemic exposure to *d*-8-*p*-menthene-1,2-epoxide is below the TTC for the repeated dose toxicity endpoint of a Cramer Class III material at the current level of use.

**11.1.2.1. Risk assessment.** There are no repeated dose toxicity data on *d*-8-*p*-menthene-1,2-epoxide or any read-across materials that can be used to support the repeated dose toxicity endpoint. The total systemic exposure (0.005 µg/kg/day) is below the TTC for *d*-8-*p*-menthene-1,2-epoxide (1.5 µg/kg/day; Kroes, 2007).

**Additional References:** None.

**Literature Search and Risk Assessment Completed On:** 10/13/21.

#### 11.1.3. Reproductive toxicity

There are insufficient reproductive toxicity data on *d*-8-*p*-menthene-1,2-epoxide or any read-across materials. The total systemic exposure to *d*-8-*p*-menthene-1,2-epoxide is below the TTC for the reproductive toxicity endpoint of a Cramer Class III material at the current level of use.

**11.1.3.1. Risk assessment.** There are no reproductive toxicity data on *d*-8-*p*-menthene-1,2-epoxide or any read-across materials that can be used to support the reproductive toxicity endpoint. The total systemic exposure (0.005 µg/kg/day) is below the TTC for *d*-8-*p*-menthene-1,2-epoxide (1.5 µg/kg/day; Kroes, 2007; Laufersweiler, 2012).

**Additional References:** None.

**Literature Search and Risk Assessment Completed On:** 10/28/21.

#### 11.1.4. Skin sensitization

Based on existing data and the application of DST, *d*-8-*p*-menthene-1,2-epoxide does not present a safety concern for skin sensitization under the current, declared levels of use.

**11.1.4.1. Risk assessment.** The chemical structure of this material

indicates that it would be expected to react with skin proteins (Roberts, 2007; Toxtree v3.1.0; OECD Toolbox v4.2). No predictive skin sensitization studies are available for *d*-8-*p*-menthene-1,2-epoxide. However, in a Confirmation of No Induction in Humans test (CNIH) with 10% (7752 µg/cm<sup>2</sup>) *d*-8-*p*-menthene-1,2-epoxide in alcohol SDA 39C, no skin sensitization reactions were observed in any of the 36 volunteers (RIFM, 1973). Acting conservatively due to the limited data, the reported exposure was benchmarked utilizing the reactive DST of 64 µg/cm<sup>2</sup> (Safford, 2008, 2011, 2015b; Roberts, 2015). The current exposure from the 95th percentile concentration is below the DST for reactive materials when evaluated in all QRA categories. Table 1 provides the maximum acceptable concentrations for *d*-8-*p*-menthene-1,2-epoxide that present no appreciable risk for skin sensitization based on the reactive DST. These levels represent maximum acceptable concentrations based on the DST approach. However, additional studies may show it could be used at higher levels.

**Additional References:** None.

**Literature Search and Risk Assessment Completed On:** 10/21/21.

**Table 1**

Maximum acceptable concentrations for *d*-8-*p*-menthene-1,2-epoxide that present no appreciable risk for skin sensitization based on reactive DST.

| IFRA Category <sup>a</sup> | Description of Product Type  | Maximum Acceptable Concentrations in Finished Products Based on Reactive DST | Reported 95th Percentile Use Concentrations in Finished Products |
|----------------------------|--|--|--|
| 1                          | Products applied to the lips   | 0.0049%  | NRU <sup>b</sup>   |
| 2                          | Products applied to the axillae  | 0.0015%  | 1.2 × 10 <sup>-5</sup> %   |
| 3                          | Products applied to the face using fingertips  | 0.029%   | NRU <sup>b</sup>   |
| 4                          | Fine fragrance products  | 0.027%   | 8.7 × 10 <sup>-4</sup> %   |
| 5                          | Products applied to the face and body using the hands (palms), primarily leave-on                  | 0.0070%  | 6.0 × 10 <sup>-5</sup> %   |
| 6                          | Products with oral and lip exposure  | 0.016%   | NRU <sup>b</sup>   |
| 7                          | Products applied to the hair with some hand contact  | 0.056%   | NRU <sup>b</sup>   |
| 8                          | Products with significant anogenital exposure  | 0.0029%  | No Data <sup>c</sup>   |
| 9                          | Products with body and hand exposure, primarily rinse-off  | 0.054%   | 5.6 × 10 <sup>-5</sup> %   |
| 10                         | Household care products with mostly hand contact   | 0.19%  | 6.0 × 10 <sup>-5</sup> %   |
| 11                         | Products with intended skin contact but minimal transfer of fragrance to skin from inert substrate | 0.11%  | No Data <sup>c</sup>   |
| 12                         | Products not intended for direct skin contact, minimal or insignificant transfer to skin           | Not restricted   | 9.0 × 10 <sup>-5</sup> %   |

Note.

<sup>a</sup> For a description of the categories, refer to the IFRA/RIFM Information Booklet.

<sup>b</sup> No reported use.

<sup>c</sup> Fragrance exposure from these products is very low. These products are not currently in the Creme RIFM Aggregate Exposure Model.

### 11.1.5. Phototoxicity/photoallergenicity

Based on the available UV/Vis spectra, *d*-8-*p*-menthene-1,2-epoxide would not be expected to present a concern for phototoxicity or photoallergenicity.

**11.1.5.1. Risk assessment.** There are no phototoxicity studies available for *d*-8-*p*-menthene-1,2-epoxide in experimental models. UV/Vis absorption spectra indicate no absorption between 290 and 700 nm. The corresponding molar absorption coefficient is below the benchmark of concern for phototoxicity and photoallergenicity (Henry, 2009). Based on the lack of absorbance, *d*-8-*p*-menthene-1,2-epoxide does not present a concern for phototoxicity or photoallergenicity.

**11.1.5.2. UV spectra analysis.** UV/Vis absorption spectra (OECD TG 101) were obtained. The spectra indicate no absorbance in the range of 290–700 nm. The molar absorption coefficient is below the benchmark of concern for phototoxic effects, 1000 L mol<sup>-1</sup> • cm<sup>-1</sup> (Henry, 2009).

**Additional References:** None.

**Literature Search and Risk Assessment Completed On:** 10/13/21.

### 11.1.6. Local Respiratory Toxicity

The margin of exposure could not be calculated due to a lack of appropriate data. The exposure level for *d*-8-*p*-menthene-1,2-epoxide is below the Cramer Class III TTC value for inhalation exposure local effects.

**11.1.6.1. Risk assessment.** There are no inhalation data available on *d*-8-*p*-menthene-1,2-epoxide. Based on the Creme RIFM Model, the inhalation exposure is 0.000012 mg/day. This exposure is 39167 times lower than the Cramer Class III TTC value of 0.47 mg/day (based on human lung weight of 650 g; Carthew, 2009); therefore, the exposure at the current level of use is deemed safe.

**Additional References:** None.

**Literature Search and Risk Assessment Completed On:** 11/15/21.

## 11.2. Environmental endpoint summary

### 11.2.1. Screening-level assessment

A screening-level risk assessment of *d*-8-*p*-menthene-1,2-epoxide was performed following the RIFM Environmental Framework (Salvito, 2002), which provides 3 tiered levels of screening for aquatic risk. In Tier 1, only the material's regional VoU, its log K<sub>OW</sub>, and its molecular weight are needed to estimate a conservative risk quotient (RQ), expressed as the ratio Predicted Environmental Concentration/Predicted No Effect Concentration (PEC/PNEC). A general QSAR with a high uncertainty factor applied is used to predict fish toxicity, as discussed in Salvito et al. (2002). In Tier 2, the RQ is refined by applying a lower uncertainty factor to the PNEC using the ECOSAR model (US

EPA, 2012b), which provides chemical class-specific ecotoxicity estimates. Finally, if necessary, Tier 3 is conducted using measured biodegradation and ecotoxicity data to refine the RQ, thus allowing for lower PNEC uncertainty factors. The data for calculating the PEC and PNEC for this safety assessment are provided in the table below. For the PEC, the range from the most recent IFRA Volume of Use Survey is reviewed. The PEC is then calculated using the actual regional tonnage, not the extremes of the range. Following the RIFM Environmental Framework, *d*-8-*p*-menthene-1,2-epoxide was identified as a fragrant material with no potential to present a possible risk to the aquatic environment (i.e., its screening-level PEC/PNEC <1).

A screening-level hazard assessment using EPI Suite v4.11 (US EPA, 2012a) identified *d*-8-*p*-menthene-1,2-epoxide as possibly persistent but not bioaccumulative based on its structure and physical-chemical properties. This screening-level hazard assessment considers the potential for a material to be persistent and bioaccumulative and toxic, or very persistent and very bioaccumulative as defined in the Criteria Document (Api, 2015). As noted in the Criteria Document, the screening criteria applied are the same as those used in the EU for REACH (ECHA, 2012). For persistence, if the EPI Suite model BIOWIN 3 predicts a value < 2.2 and either BIOWIN 2 or BIOWIN 6 predicts a value < 0.5, then the material is considered potentially persistent. A material would be considered potentially bioaccumulative if the EPI Suite model BCFBAF predicts a fish BCF ≥2000 L/kg. Ecotoxicity is determined in the above screening-level risk assessment. If, based on these model outputs (Step 1), additional assessment is required, a WoE-based review is then performed (Step 2). This review considers available data on the material's physical-chemical properties, environmental fate (e.g., OECD Guideline biodegradation studies or die-away studies), fish bioaccumulation, and higher-tier model outputs (e.g., US EPA's BIOWIN and BCFBAF found in EPI Suite v4.11).

**11.2.1.1. Risk assessment.** Based on the current Volume of Use (2015), *d*-8-*p*-menthene-1,2-epoxide presents no risk to the aquatic compartment in the screening-level assessment.

### 11.2.2. Key studies

**11.2.2.1. Biodegradation.** No data available.

**11.2.2.2. Ecotoxicity.** No data available.

**11.2.2.3. Other available data.** *d*-8-*p*-Menthene-1,2-epoxide has been pre-registered for REACH with no additional information available at this time.

**11.2.2.4. Risk assessment refinement.** Ecotoxicological data and PNEC derivation (all endpoints reported in mg/L; PNECs in µg/L).

Endpoints used to calculate PNEC are underlined.

|  | LC50 (Fish)<br>(mg/L) | EC50<br>( <i>Daphnia</i> )<br>(mg/L) | EC50<br>(Algae)<br>(mg/L) | AF      | PNEC (µg/L) | Chemical Class |
|--|-----------------------|--------------------------------------|---------------------------|---------|-------------|----------------|
| RIFM Framework<br>Screening-level (Tier 1) | <u>11.71</u>          |                                      |                           | 1000000 | 0.01171     |                |

Exposure information and PEC calculation (following RIFM Environmental Framework: [Salvito et al., 2002](#)).

| Exposure                               | Europe (EU) | North America (NA) |
|--|-------------|--------------------|
| Log Kow Used                           | 3.43        | 3.43               |
| Biodegradation Factor Used             | 0           | 0                  |
| Dilution Factor                        | 3           | 3                  |
| Regional Volume of Use Tonnage Band*   | <1          | No VoU             |
| <b>Risk Characterization: PEC/PNEC</b> | <1          | NA                 |

\*Combined Regional Volume of Use for both CAS #s.

Based on available data, the RQ for this material is < 1. No further assessment is necessary.

The RIFM PNEC is 0.01171 µg/L. The revised PEC/PNECs for EU and NA (No VoU) are not applicable. The material was cleared at the screening-level; therefore, it does not present a risk to the aquatic environment at the current reported volumes of use.

**Literature Search and Risk Assessment Completed On:** 11/15/21.

## 12. Literature Search\*

- **RIFM Database:** Target, Fragrance Structure-Activity Group materials, other references, JECFA, CIR, SIDS
- **ECHA:** <https://echa.europa.eu/>
- **NTP:** <https://ntp.niehs.nih.gov/>
- **OECD Toolbox:** <https://www.oecd.org/chemicalsafety/risk-assessment/oecd-qsar-toolbox.htm>
- **SciFinder:** <https://scifinder.cas.org/scifinder/view/scifinder/scifinderExplore.jsf>
- **PubMed:** <https://www.ncbi.nlm.nih.gov/pubmed>
- **National Library of Medicine's Toxicology Information Services:** <https://toxnet.nlm.nih.gov/>
- **IARC:** <https://monographs.iarc.fr>
- **OECD SIDS:** <https://hvpchemicals.oecd.org/ui/Default.aspx>
- **EPA ACToR:** <https://actor.epa.gov/actor/home.xhtml>
- **US EPA HPVIS:** [https://ofmpub.epa.gov/opthpv/public\\_search\\_publicdetails?submission\\_id=24959241&ShowComments=Yes&sqlstr=null&recordcount=0&User\\_title=DetailQuery%20Results&EndPointRpt=Y#submission](https://ofmpub.epa.gov/opthpv/public_search_publicdetails?submission_id=24959241&ShowComments=Yes&sqlstr=null&recordcount=0&User_title=DetailQuery%20Results&EndPointRpt=Y#submission)
- **Japanese NITE:** [https://www.nite.go.jp/en/chem/chrip/chrip\\_search/systemTop](https://www.nite.go.jp/en/chem/chrip/chrip_search/systemTop)
- **Japan Existing Chemical Data Base (JECDB):** [http://dra4.nihs.go.jp/mhlw\\_data/jsp/SearchPageENG.jsp](http://dra4.nihs.go.jp/mhlw_data/jsp/SearchPageENG.jsp)
- **Google:** <https://www.google.com>
- **ChemIDplus:** <https://chem.nlm.nih.gov/chemidplus/>

Search keywords: CAS number and/or material names.

\*Information sources outside of RIFM's database are noted as appropriate in the safety assessment. This is not an exhaustive list. The links listed above were active as of 12/15/21.

## Declaration of competing interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. We wish to confirm that there are no known conflicts of interest associated with this publication and there has been no significant financial support for this work that could have influenced its outcome. RIFM staff are employees of the Research Institute for Fragrance Materials, Inc. (RIFM). The Expert Panel receives a small honorarium for time spent reviewing the subject work.

## References

- Api, A.M., Belsito, D., Bruze, M., Cadby, P., Calow, P., Dagli, M.L., Dekant, W., Ellis, G., Fryer, A.D., Fukayama, M., Griem, P., Hickey, C., Kromidas, L., Lalko, J.F., Liebler, D.C., Miyachi, Y., Politano, V.T., Renskers, K., Ritacco, G., Salvito, D., Schultz, T.W., Sipes, I.G., Smith, B., Vitale, D., Wilcox, D.K., 2015. Criteria for the Research Institute for fragrance materials, Inc. (RIFM) safety evaluation process for fragrance ingredients. *Food and Chemical Toxicology* 82, S1–S19.
- Carthew, P., Clapp, C., Gutsell, S., 2009. Exposure based waiving: the application of the toxicological threshold of concern (TTC) to inhalation exposure for aerosol ingredients in consumer products. *Food and Chemical Toxicology* 47 (6), 1287–1295.
- Comiskey, D., Api, A.M., Barratt, C., Daly, E.J., Ellis, G., McNamara, C., O'Mahony, C., Robison, S.H., Safford, B., Smith, B., Tozer, S., 2015. Novel database for exposure to fragrance ingredients in cosmetics and personal care products. *Regulatory Toxicology and Pharmacology* 72 (3), 660–672.
- Comiskey, D., Api, A.M., Barrett, C., Ellis, G., McNamara, C., O'Mahony, C., Robison, S.H., Rose, J., Safford, B., Smith, B., Tozer, S., 2017. Integrating habits and practices data for soaps, cosmetics and air care products into an existing aggregate exposure model. *Regulatory Toxicology and Pharmacology* 88, 144–156.
- ECHA, 2012. *Guidance on Information Requirements and Chemical Safety Assessment Chapter R.11: PBT Assessment, November 2012 v1.1.* <http://echa.europa.eu/>.
- Henry, B., Foti, C., Alsante, K., 2009. Can light absorption and photostability data be used to assess the photosafety risks in patients for a new drug molecule? *Journal of Photochemistry and Photobiology B: Biology* 96 (1), 57–62.
- IFRA (International Fragrance Association), 2015. *Volume of Use Survey.* February 2015.
- Kirkland, D., Zeiger, E., Madia, F., Gooderham, N., Kasper, P., et al., 2014. Can in vitro mammalian cell genotoxicity test results be used to complement positive results in the Ames test and help predict carcinogenic or in vivo genotoxic activity? I. Reports of individual databases presented at an EURL ECVAM workshop. *Mutation Research/Genetic Toxicology and Environmental Mutagenesis* 775–776, 55–68.
- Kroes, R., Renwick, A.G., Feron, V., Galli, C.L., Gibney, M., Greim, H., Guy, R.H., Lhuguenot, J.C., van de Sandt, J.J.M., 2007. Application of the threshold of toxicological concern (TTC) to the safety evaluation of cosmetic ingredients. *Food and Chemical Toxicology* 45 (12), 2533–2562.
- Laufersweiler, M.C., Gadagbui, B., Baskerville-Abraham, I.M., Maier, A., Willis, A., et al., 2012. Correlation of chemical structure with reproductive and developmental toxicity as it relates to the use of the threshold of toxicological concern. *Regulatory Toxicology and Pharmacology* 62 (1), 160–182.
- Na, M., Ritacco, G., O'Brien, D., Lavelle, M., Api, A., Basketter, D., 2021. Fragrance skin sensitization evaluation and human testing: 30-year experience. *Dermatitis* 32 (5), 339–352.
- RIFM (Research Institute for Fragrance Materials, Inc.), 1973. *Repeated Insult Patch Test with D-8-P-Menthene-1,2-Epoxyde.* Unpublished Report from International Flavors and Fragrances. RIFM Report Number 57390. RIFM, Woodcliff Lake, NJ, USA.
- RIFM (Research Institute for Fragrance Materials, Inc.), 2017a. *d-8-p-menthene-1,2-epoxyde: in Vitro Human Lymphocyte Micronucleus Assay.* RIFM, Woodcliff Lake, NJ, USA [Report Amendment Attached] RIFM report number 71606.
- RIFM (Research Institute for Fragrance Materials, Inc.), 2017b. *d-8-p-menthene-1,2-epoxyde: Bacterial Reverse Mutation Assay: Plate Incorporation Method with a Confirmatory Assay.* RIFM Report Number 72516. RIFM, Woodcliff Lake, NJ, USA.
- RIFM (Research Institute for Fragrance Materials, Inc.), 2018. *d-8-p-menthene-1,2-epoxyde: in Vitro L5178Y Gene Mutation Assay at the HPRT Locus.* RIFM Report Number 77953. RIFM, Woodcliff Lake, NJ, USA.
- RIFM (Research Institute for Fragrance Materials, Inc.), 2019. *Exposure Survey 23.* January 2019.
- RIFM (Research Institute for Fragrance Materials, Inc.), 2021. *d-8-p-menthene-1,2-epoxyde: in Vitro Alkaline Comet Assay in Reconstructed 3D Full Thickness Human Skin Models.* RIFM Report Number 77951. RIFM, Woodcliff Lake, NJ, USA.
- Roberts, D.W., Api, A.M., Safford, R.J., Lalko, J.F., 2015. Principles for identification of high potency category chemicals for which the dermal sensitization threshold (DST) approach should not be applied. *Regulatory Toxicology and Pharmacology* 72 (3), 683–693.
- Roberts, D.W., Patlewicz, G., Kern, P.S., Gerberick, F., Kimber, I., Dearman, R.J., Ryan, C.A., Basketter, D.A., Aptula, A.O., 2007. Mechanistic applicability domain classification of a local lymph node assay dataset for skin sensitization. *Chemical Research in Toxicology* 20 (7), 1019–1030.
- Safford, B., Api, A.M., Barratt, C., Comiskey, D., Daly, E.J., Ellis, G., McNamara, C., O'Mahony, C., Robison, S., Smith, B., Thomas, R., Tozer, S., 2015b. Use of an aggregate exposure model to estimate consumer exposure to fragrance ingredients in personal care and cosmetic products. *Regulatory Toxicology and Pharmacology* 72, 673–682.
- Safford, B., Api, A.M., Barratt, C., Comiskey, D., Ellis, G., McNamara, C., O'Mahony, C., Robison, S., Rose, J., Smith, B., Tozer, S., 2017. Application of the expanded Creme RIFM consumer exposure model to fragrance ingredients in cosmetic, personal care and air care products. *Regulatory Toxicology and Pharmacology* 86, 148–156.
- Safford, R.J., 2008. The dermal sensitisation threshold—A TTC approach for allergic contact dermatitis. *Regulatory Toxicology and Pharmacology* 51 (2), 195–200.
- Safford, R.J., Api, A.M., Roberts, D.W., Lalko, J.F., 2015a. Extension of the dermal sensitization threshold (DST) approach to incorporate chemicals classified as reactive. *Regulatory Toxicology and Pharmacology* 72 (3), 694–701.

Safford, R.J., Aptula, A.O., Gilmour, N., 2011. Refinement of the dermal sensitisation threshold (DST) approach using a larger dataset and incorporating mechanistic chemistry domains. *Regulatory Toxicology and Pharmacology* 60 (2), 218–224.

Salvito, D.T., Senna, R.J., Federle, T.W., 2002. A Framework for prioritizing fragrance materials for aquatic risk assessment. *Environmental Toxicology and Chemistry* 21 (6), 1301–1308.

US EPA, 2012a. Estimation Programs Interface Suite for Microsoft Windows, v4.0–v4.11. United States Environmental Protection Agency, Washington, DC, USA.

US EPA, 2012b. The ECOSAR (ECOLOGical Structure Activity Relationship) Class Program for Microsoft Windows, v1.11. United States Environmental Protection Agency, Washington, DC, USA.